Compare SER & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | NRSN |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 26.4M |
| IPO Year | 2018 | 2021 |
| Metric | SER | NRSN |
|---|---|---|
| Price | $2.01 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $13.00 | ★ $14.00 |
| AVG Volume (30 Days) | 24.7K | ★ 364.9K |
| Earning Date | 11-13-2025 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,000.00 | N/A |
| Revenue This Year | $134.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $0.68 |
| 52 Week High | $7.92 | $2.60 |
| Indicator | SER | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 26.75 | 36.78 |
| Support Level | $1.71 | $0.68 |
| Resistance Level | $2.75 | $0.91 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 21.77 | 36.29 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.